Clinical and serological features of acute sensory ataxic neuropathy with antiganglioside antibodies

• Published in: Journal of the peripheral nervous system Vol. 17; no. 2; pp. 158 - 168
• Main Authors: Rojas-García, Ricard, Querol, Luis, Gallardo, Eduard, De Luna Salva, Noemi, Juarez, Cándido, Garces, Mercedes, Fages, Eva, Casasnovas, Carlos, Illa, Isabel
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.06.2012
• Subjects: acute sensory ataxic neuropathy; Adult; Aged; antiganglioside antibodies; Ataxia; Autoantibodies - blood; Autoantigens - immunology; disialosyl; Enzyme-Linked Immunosorbent Assay; Epitopes; Female; Gangliosides; Gangliosides - immunology; Guillain-Barre syndrome; Guillain-Barre Syndrome - immunology; Guillain-Barré syndrome; Humans; Immunoglobulin G; Male; Middle Aged; Muscles; Neuropathy; Ophthalmoplegia; Peripheral Nervous System Diseases - blood; Peripheral Nervous System Diseases - classification; Peripheral Nervous System Diseases - immunology; Prognosis; Proprioception; Retrospective Studies; Young Adult
• ISSN: 1085-9489; 1529-8027; 1529-8027
• DOI: 10.1111/j.1529-8027.2012.00407.x

There is as yet no consensus for considering pure acute sensory ataxic neuropathy (ASAN) as a variant of Guillain‐Barré syndrome (GBS). Reactivity against gangliosides sharing disialosyl epitopes has been reported in these patients. The aim of this study was to determine the spectrum of reactivity against gangliosides in ASAN and to define the clinical pattern. From our database we identified patients with suspicion of ASAN. We defined ASAN as the presence of ataxia of peripheral origin with loss of proprioception, and areflexia, absence of ophthalmoplegia and no or minimal muscle weakness. Patients who met these criteria were retrospectively reviewed for their spectrum of reactivity against gangliosides and clinical features. We identified 12 patients fulfilling pre‐defined criteria for ASAN. Reactivity against gangliosides containing disialosyl epitopes was present in seven patients. Concomitant reactivity against other gangliosides was present in 6/7 patients. All patients presented good prognosis and an antecedent illness was present in nine. Our results support the previously described clinico‐immunological association between ASAN and disialosyl specificity, and widen the spectrum of reactivity against gangliosides. The acute presentation with a monophasic course, and good prognosis in all cases, together with transient immunoglobulin G antiganglioside antibodies and infectious antecedent in 7/12 patients support the inclusion of ASAN as a GBS variant.